Am J Health-Syst Pharm
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Beier, M. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Beier, M. T.

Pharmacotherapy for behavioral and psychological symptoms of dementia in the elderly

Manju T. Beier

MANJU T. BEIER, PHARM.D., FASCP, is Senior Partner, Geriatric Consultant Resources LLC, and Clinical Associate Professor of Pharmacy, The University of Michigan, 428 Church St., Ann Arbor, MI 48109 (tanja{at}umich.edu).


Purpose. The use of atypical antipsychotics for maximizing clinical efficacy and overall health in patients with neuropsychiatric symptoms of dementia is discussed.

Summary. Psychotic and behavioral symptoms are common among older patients with dementia, and an accurate diagnosis can be obscured by complex presentation of symptoms and comorbidities. When initiating pharmacotherapy in this patient population, it is important to consider the increased presence of comorbidities and the additive pharmacologic effects of concomitantly administered drugs. Atypical antipsychotics are among the most well-studied therapeutic classes of psychoactive medications and are frequently utilized for treating psychotic symptoms and agitation in the elderly. These medications have distinct pharmacologic profiles with different liabilities for adverse effects such as sedation, metabolic disturbances, and anticholinergic effects. Recent findings from the Clinical Antipsychotic Trials of Intervention Effectiveness—Alzheimer’s Disease (CATIE-AD) study demonstrate that although these agents have some efficacy, their adverse effects may limit their utility in patients.

Conclusion. The adverse effect profile should be an important consideration for clinicians selecting an atypical antipsychotic for use in this population.

Index terms: Antipsychotic agents; Dementia; Diagnosis; Drug interactions; Drugs; Geriatrics; Mechanism of action; Toxicity

 





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the American Society of Health-System Pharmacists.